key: cord-0946022-37agxwqn authors: Biradar, Vivek; Konnur, Abhijit; Gang, Sishir; Hegde, Umapati; Rajapurkar, Mohan; Patel, Hardik; Pandey, Sachidanand; Soni, Shailesh title: Adult-onset nephrotic syndrome following COVID-19 vaccination date: 2021-08-28 journal: Clin Kidney J DOI: 10.1093/ckj/sfab153 sha: 704ca7141947354cb45d316733f0d0b60e192233 doc_id: 946022 cord_uid: 37agxwqn A 22-year-old healthy man was admitted for edema 15 days after the first injection of the COVISHIELD COVID-19 vaccine (Oxford AstraZeneca) vaccine. Nephrotic syndrome was diagnosed and a kidney biopsy showed minimal change disease. Oral Prednisolone was started at 1mg/kg/day resulting in complete remission within one week. The pandemic of coronavirus disease (COVID-19) represents a multi-faceted challenge for healthcare systems across the globe. The advent of novel vaccines is claimed to be a game changer in the battle with this pandemic. Though benefits of vaccine in preventing coronavirus disease is proven and most of the side effects occur on the day of vaccination (6 to 8 hours later) and resolve within 2 to 3 days. Does the COVID-19 vaccine trigger an onset of nephrotic syndrome or other renal disease and other major side-effects is still unknown. We report a case of development of minimal change disease (MCD) with nephrotic syndrome and deranged liver enzymes, starting a few days after administration of the first injection of the COVISHIELD COVID-19 vaccine (Oxford AstraZeneca). A 22-year-old previously healthy man was admitted to our centre following the appearance of periorbital and bilateral lower limb swelling. Fifteen days earlier, he had received the first injection of the COVISHIELD COVID-19 vaccine (Oxford AstraZeneca) at an authorized centre under medical supervision. On the same day he had generalized weakness and body ache for which he took paracetamol 650 mg two tablets. A week later he noticed yellowish discoloration of urine and 4 days later developed sudden onset of periorbital and bilateral lower limb swelling. A preemployment laboratory tests 5 months earlier had been normal, with serum creatinine 0.70 mg/dL and normal urinalysis. The patient took 2 tablets of paracetamol but denied use of nonsteroidal anti-inflammatory drugs or alternative medications before or after the vaccination. On admission, blood pressure was 130/70 mm Hg and heart rate 76 beats/min. Physical examination revealed pitting edema in the lower extremities. Systemic examination was unremarkable. Laboratory tests revealed serum creatinine 0.72 mg/dL, serum albumin 2.33 g/dL, cholesterol 401 mg/dL, and triglycerides 193 mg/dL. Urine microscopy showed 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 He was started on tablet prednisolone 1mg/kg/day dose and on follow up after one week patient achieved remission with UPCR 0.15:1 mg/mg, urine microscopy showed absent protein and increasing serum albumin to 2.8 g/dl from 2.33 g/dl on first visit. Transaminitis also showed improvement. In MCD existence of an abnormal T-cells producing circulating mediator was postulated as far back as 1974 by Shalhoub 1 , and clinical and experimental studies 2,3 have given evidence of imbalance in T cell subpopulations during active phase of disease, with a prevalence of circulating CD8+ T suppressor cells, aggravating renal damage in mouse models of nephrotic syndrome 4 and a prevalence of a Th2 cell (Th2; IL4, IL5, IL9, IL10, and IL13) cytokine profile in patients 5 , which is similar to the spontaneous model of idiopathic nephrotic syndrome in the Buffalo/Mna rat 6 . These observations are similar to clinical observation of an association between MCD and atopy, as allergies are driven by Th2 responses. Proteinuria including new onset MCD and relapse of MCD after COVID infection has been reported 7 . The exact cause for podocyte injury is unknown. The cytokine storm generating an immunological milieu with excessive production of Th2-generated cytokines act as a trigger for the podocytopathy. In some immune mechanisms can result in immune complex deposition in the glomeruli leading to glomerulonephritis. It is speculated that the systemic T cell dysfunction results in the production of a glomerular permeability factor. This circulating factor directly induces foot process fusion resulting in severe alteration of the glomerular filtration and resulting marked proteinuria 8 Finding from single-dose Covishield covid-19 vaccine study 9 showed vaccination induced Sprotein-reactive CD4 + T and CD8 + T cells with a T helper 1 (T H 1)-type cytokine bias as well as CD8 + T cells with a cytotoxic phenotype. T H 1-type immunity is thought to mediate protective antiviral immunity whereas T H 2-type responses have been linked with potentially adverse vaccine effects. Robust B cell activation and proliferation were also observed after a single dose and anti-S protein IgG (predominantly the T H 1-associated IgG1 and IgG3 isotypes) were detected by day 14 and maintained at day 56. There are 3 case reports of MCD post vaccination with HBV 10,11,12 and 1 each after pneumococcus 13 , influenza 14 , tetanus-diphtheria-poliomyelitis 8 meningococcal C vaccines 15 and Pfizer covid-19 vaccination 16 with mean duration ranging between 4 days to 4 months. Relapse of MCD has been documented after AstraZeneca vaccine 17 . Our case report raises the question of either possible causation or association of MCD with covid vaccination which cannot be attributed yet without more reports of similar cases. We suggest, therefore, that patients who develop nephrotic syndrome following COVID-19 vaccination should undergo a kidney biopsy. If MCD is confirmed, prompt initiation of 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 http://mc.manuscriptcentral.com/ckj Clinical Kidney Journal 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 Pathogenesis of Lipoid Nephrosis: A Disorder of T-Cell Function The Role of the Immune System in Idiopathic Nephrotic Syndrome: A Review of Clinical and Experimental Studies Nephrotic Syndrome Relapse in a Boy with COVID-19 Minimal Change Nephrotic Syndrome in an 82 Year Old Patient Following a Tetanus-Diphteria-Poliomyelitis-Vaccination Immune Readouts from the Oxford COVID-19 Vaccine Nephrotic Syndrome Associated with Recombinant Hepatitis B Vaccination: A Causal Relationship or Just a Mere Association? Nephrotic Syndrome Following Hepatitis B Vaccination Nephrotic Syndrome after Recombinant Hepatitis B Vaccine Minimal Change Nephrotic Syndrome, Lymphadenopathy and Hyperimmunoglobulinemia after Immunization with a Pneumococcal Vaccine Minimal Change Nephrotic Syndrome in a 65-Year-Old Patient Following Influenza Vaccination Vaccine in Nephrotic Syndrome Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine Relapse of Minimal Change Disease Following the AstraZeneca COVID-19 Vaccine None declared.